The manifestation of features of opioids and narcotics using by drug addicted people and the role of replacement pharmacotherapy in treatment and recovery of the patient


  • Nodar Sulashvili Tbilisi State Medical University; Sulkhan-Saba Orbeliani University; Alte University; Shota Meskhia Zugdidi State University; David Aghmashenebeli University of Georgia; University of Georgia, Georgia
  • Nino Abuladze Akaki Tsereteli State University, Georgia
  • Margarita Beglaryan Yerevan State Medical University after Mkhitar Heratsi, Armenia
  • Jilda Cheishvili Sulkhan-Saba Orbeliani University, Georgia
  • Ada (Adel) Tadevosyan Yerevan State Medical University after Mkhitar Heratsi, Armenia
  • Marika Sulashvil Tbilisi State Medical University; Sulkhan-Saba Orbeliani University, Georgia



Opioid, dependent, drug, addiction, patients, methadone, replacement therapy


Aim of the research was to study and analyze the features of opioids and narcotics using by drug addicted people and the role of replacement drugs in treatment and recovery of the patient.

Materials and methods: We conducted a systematic review and meta-analysis of studies. Were used Systematic literature reviews and meta-analyses. The material of the article was data from the scientific literature, processed and analyzed by generalization and systematization. The scientific research ensues the fundamentals of assessment development of significant reviews. The ensuing databases were used: (for searching considerable literature to study and analyze the features of opioids and narcotics using by drug addiction people and the role of replacement drugs in treatment and recovery of the patient) Pub Med, Web of Science, Clinical key, Tomson Routers, Google Scholar, Cochrane Library, and Elsevier bases. Additionally studied national and internationals policy and guidelines and also grey literature.

Results: Addiction is well known to be associated with its high level of physical and mental disorders. Most chronic chemical dependencies of drug addiction are also associated with its very high mortality rates, estimated to be several times those of the non-clinical population. Since addictive substances are known to disrupt cell growth and cell division, it can be assumed, that they particularly affect dividing cells, such as stem cell pools and progenitor cells. It is also known, that they either individually or in combination potentiate apoptosis, i.e., contribute to this effect. The medicine of aging in recent times has become an independent scientific discipline. The cellular aging hypothesis suggests the aging phenotype. The organism is associated with cellular correlates of age associated changes including cell loss, reduced cell velocity, renewal and more aging, negligible functional and non-replicating cells in tissues. So, the anti-growth effects of drug addiction can reasonably occur throughout the body. Expect signs of accelerated aging to be evident. One would expect such a putative progeroid effect to occur subject to increased morbidity and mortality rates, clinically observed almost identically in drug addicts as is the case in the geriatric population. In this connection there are various changes, consideration of all clinical aspects’ expression of this general toxicology hypothesis of opioids is needed.

Conclusion: Pharmacological management of drug use should be only one component of treatment for drug needs, tailored to a comprehensive needs assessment of the child or young person, carried out in conjunction with appropriate psychological therapy and mental health interventions, and in the context of a clear and applied approach to the clinical management system. Caution is required when leaving these establishments due to the risk of overdose and in the transition to adult services. Physicians should carefully consider the degree of dependence on any substance, especially when alcohol and other substances, such as opiates, are used together. The full implementation of treatment, rehabilitation and harm reduction services will reduce the negative health, social and economic consequences of drug use for individuals, communities and society as a whole. The number of drug users will increase, those involved in counseling, treatment, rehabilitation and harm reduction programs

Author Biographies

Nodar Sulashvili, Tbilisi State Medical University; Sulkhan-Saba Orbeliani University; Alte University; Shota Meskhia Zugdidi State University; David Aghmashenebeli University of Georgia; University of Georgia

MD, PhD, Doctor of Theoretical Medicine in Pharmaceutical and Pharmacological Sciences, Invited Professor, Lecturer

Scientific Research-Skills Center;

Associate Professor;

Associate Professor

Division of Pharmacology International School of Medicine;

Associate Professor

Pharmacy Program;

Associate Professor

School of Medicine;

Associate Professor

School of Health Sciences

Nino Abuladze, Akaki Tsereteli State University

MD, PhD, Doctor of Pharmaceutical Sciences, Professor

Department of Stomatology and Pharmacy

Margarita Beglaryan, Yerevan State Medical University after Mkhitar Heratsi

MD, PhD, Doctor of Pharmaceutical Sciences, Professor, Head of Department

Department of Pharmaceutical Management and Pharmaceutics

Jilda Cheishvili, Sulkhan-Saba Orbeliani University

MD, PhD, Doctor of Medical Sciences, Professor, Dean of Faculty

Faculty of Medicine

Ada (Adel) Tadevosyan, Yerevan State Medical University after Mkhitar Heratsi

MD, PhD, Doctor of Medical Sciences, Academician, Professor

Department of Psychiatry and Stressology

Marika Sulashvil, Tbilisi State Medical University; Sulkhan-Saba Orbeliani University

MD, Doctor of Family Medicine, Lecturer

Department of Molecular and Medical Genetics

Invited Lecturer

Faculty of Medicine


  1. Vindegaard, N., Benros, M. E. (2020). COVID-19 pandemic and mental health consequences: Systematic review of the current evidence. Brain, Behavior, and Immunity, 89, 531–542. doi:
  2. Carvalho-Schneider, C., Laurent, E., Lemaignen, A., Beaufils, E., Bourbao-Tournois, C., Laribi, S. et al. (2021). Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clinical Microbiology and Infection, 27 (2), 258–263. doi:
  3. Mackolil, J., Mackolil, J. (2020). Addressing psychosocial problems associated with the COVID-19 lockdown. Asian Journal of Psychiatry, 51. doi:
  4. Holingue, C., Kalb, L. G., Riehm, K. E., Bennett, D., Kapteyn, A., Veldhuis, C. B. et al. (2020). Mental Distress in the United States at the Beginning of the COVID-19 Pandemic. American Journal of Public Health, 110 (11), 1628–1634. doi:
  5. Krishnamoorthy, Y., Nagarajan, R., Saya, G. K., Menon, V. (2020). Prevalence of psychological morbidities among general population, healthcare workers and COVID-19 patients amidst the COVID-19 pandemic: A systematic review and meta-analysis. Psychiatry Research, 293, 113382. doi:
  6. Degenhardt, L., Charlson, F., Ferrari, A., Santomauro, D., Erskine, H., Mantilla-Herrara, A. et al. (2018). The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Psychiatry, 5 (12), 987–1012. doi:
  7. Stanaway, J. D., Afshin, A., Gakidou, E., Lim, S. S., Abate, D., Abate, K. H. et al. (2018). Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet, 392 (10159), 1923–1994. doi:
  8. How Does Stress Relate to Drug Abuse? Available at: Last accessed: 17.08.2020
  9. Binswanger, I. A., Nowels, C., Corsi, K. F., Glanz, J., Long, J., Booth, R. E., Steiner, J. F. (2012). Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors. Addiction Science & Clinical Practice, 7 (1). doi:
  10. Chandler, R. K., Fletcher, B. W., Volkow, N. D. (2009). Treating Drug Abuse and Addiction in the Criminal Justice System. JAMA, 301 (2), 183–190. doi:
  11. Reuter, H. P., Trautmann, F., Liccardo Pacula, R., Kilmer, B., Gageldonk, A., Gouwe, D. (2009). Assessing Changes in Global Drug Problems. Cambridge: RAND Europe, Trimbos Institute.
  12. Transition plan/concept for the development of drug services in Georgia (2017). National Platform of Georgian Drug Policy. Tbilisi.
  13. Fishbain, D. A., Cutler, R. B., Rosomoff, H. L., Rosomoff, R. S. (2003). Are Opioid-Dependent/Tolerant Patients Impaired in Driving-Related Skills? A Structured Evidence-Based Review. Journal of Pain and Symptom Management, 25 (6), 559–577. doi:
  14. Corsenac, P., Lagarde, E., Gadegbeku, B., Delorme, B., Tricotel, A., Castot, A. et al. (2012). Road traffic crashes and prescribed methadone and buprenorphine: A french registry-based case–control study. Drug and Alcohol Dependence, 123 (1-3), 91–97. doi:
  15. Jones, H. E., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M. et al. (2010). Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure. New England Journal of Medicine, 363 (24), 2320–2331. doi:
  16. Guidelines for the identification and management of substance use and substance use disorders in pregnancy (2014). Geneva: World Health Organization.
  17. Bassetti, S., Hoffmann, M., Bucher, H. C., Fluckiger, U., Battegay, M. (2002). Infections Requiring Hospitalization of Injection Drug Users Who Participated in an Injection Opiate Maintenance Program. Clinical Infectious Diseases, 34 (5), 711–713. doi:
  18. Friedman, H., Pross, S., Klein, T. W. (2006). Addictive drugs and their relationship with infectious diseases. FEMS Immunology & Medical Microbiology, 47 (3), 330–342. doi:
  19. Reece, A. S. (2007). Evidence of accelerated ageing in clinical drug addiction from immune, hepatic and metabolic biomarkers. Immunity & Ageing, 4 (1). doi:
  20. Feng, G., Luo, Q., Guo, E., Yao, Y., Yang, F., Zhang, B., Li, L. (2015). Multiple organ dysfunction syndrome, an unusual complication of heroin intoxication: a case report and review of literature. International Journal of Clinical and Experimental Pathology, 8 (9), 11826–11830.
  21. Akhgari, M., Aleagha, A. E. (2016). Organ Toxicity Associated with Illicit Drug Use. Journal of Clinical Toxicology, 6 (6). doi:
  22. Gold, M. S., Baron, D., Bowirrat, A., Blum, K. (2020). Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome? Journal of the Neurological Sciences, 418, 117137. doi:
  23. Aronson, J. K. (2008). Routes of drug administration: uses and adverse effects. Adverse Drug Reaction Bulletin, 253, 971–974. doi:
  24. Masoomi, M., Ramezani, M. A., Shahriari, S., Shahesmaeeli, A., Mirzaeepour, F. (2010). Is opium addiction a risk factor for deep vein thrombosis? A case–control study. Blood Coagulation & Fibrinolysis, 21 (2), 109–112. doi:
  25. Volkow, N. D. (2020). Collision of the COVID-19 and Addiction Epidemics. Annals of Internal Medicine, 173 (1), 61–62. doi:
  26. Zaami, S., Marinelli, E., Varì, M. R. (2020). New Trends of Substance Abuse During COVID-19 Pandemic: An International Perspective. Frontiers in Psychiatry, 11. doi:
  27. Dubey, M. J., Ghosh, R., Chatterjee, S., Biswas, P., Chatterjee, S., Dubey, S. (2020). COVID-19 and addiction. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 14 (5), 817–823. doi:
  28. Wei, Y., Shah, R. (2020). Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications. Pharmaceuticals, 13 (7), 155. doi:
  29. Antony, A. R., Haneef, Z. (2020). Systematic review of EEG findings in 617 patients diagnosed with COVID-19. Seizure, 83, 234–241. doi:
  30. Fingelkurts, A. A., Fingelkurts, A. A., Kivisaari, R., Autti, T., Borisov, S., Puuskari, V., Jokela, O., Kähkönen, S. (2006). Increased local and decreased remote functional connectivity at EEG alpha and beta frequency bands in opioid-dependent patients. Psychopharmacology, 188 (1), 42–52. doi:
  31. Wang, G. Y., Kydd, R., Wouldes, T. A., Jensen, M., Russell, B. R. (2015). Changes in resting EEG following methadone treatment in opiate addicts. Clinical Neurophysiology, 126 (5), 943–950. doi:
  32. McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., et al. (2006). The sixth Edition of the Addiction Severity Index.
  33. Kadden, R. M., Litt, M. D. (2011). The role of self-efficacy in the treatment of substance use disorders. Addictive Behaviors, 36 (12), 1120–1126. doi:
  34. Spielberger, C. D. (2013). Manual for the State-Trait Inventory STAI (Form Y). Palo Alto.
  35. Steer, R. A., Beck, A. T., Garrison, B. (2017). Applications of the Beck Depression Inventory. Assassement of depression.
  36. Dorus, Senay, W., Edward, C. (2020). Depression, demographic dimensions, and drug abuse. Washington: American Psychological Association.
  37. Fazel, S., Bains, P., Doll, H. (2006). Substance abuse and dependence in prisoners: a systematic review. Addiction, 101 (2), 181–191. doi:
  38. The Patel report: reducing drug-related crime and rehabilitating offenders. Recovery and rehabilitation for drug users in prison and on release: recommendations for action (2010). Prison Drug Treatment Strategy Review Group. London.
  39. Ebbert, J. O., Hughes, J. R., West, R. J., Rennard, S. I., Russ, C., McRae, T. D. et al. (2015). Effect of Varenicline on Smoking Cessation Through Smoking Reduction: a randomized clinical trial. JAMA, 313 (7), 687–694. doi:
  40. Unauthored. Nicotine Replacement Therapy for Smoking Cessation or Reduction: A Review of the Clinical Evidence (2014). Ottawa: Canadian Agency for Drugs and Technologies in Health.
  41. Lüscher, C. (2016). The Emergence of a Circuit Model for Addiction. Annual Review of Neuroscience, 39 (1), 257–276. doi:
  42. Wolf, M. E. (2016). Synaptic mechanisms underlying persistent cocaine craving. Nature Reviews Neuroscience, 17 (6), 351–365. doi:




How to Cite

Sulashvili, N., Abuladze, N., Beglaryan, M., Cheishvili, J., Tadevosyan, A. (Adel), & Sulashvil, M. (2023). The manifestation of features of opioids and narcotics using by drug addicted people and the role of replacement pharmacotherapy in treatment and recovery of the patient. ScienceRise: Biological Science, (1(34), 19–30.



Biological research